Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution... – Containing or obtained from a fruit – including berry
Reexamination Certificate
2006-07-27
2010-06-01
Tate, Christopher R. (Department: 1655)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Containing or obtained from a fruit , including berry
C424S725000
Reexamination Certificate
active
07727563
ABSTRACT:
One or more embodiments of the invention are directed to methods of using pomegranate extracts for treating diabetes related atherosclerotic complications in humans. The methods comprise the step of administering to the patients a composition comprising a therapeutically effective amount of an extract from pomegranate.
REFERENCES:
patent: 5162037 (1992-11-01), Whitson-Fischman
patent: 5411733 (1995-05-01), Hozumi et al.
patent: 5433965 (1995-07-01), Fischer et al.
patent: 5624698 (1997-04-01), Dake et al.
patent: 5679351 (1997-10-01), Walter et al.
patent: 5830887 (1998-11-01), Kelly
patent: 5840308 (1998-11-01), Jassim et al.
patent: 5850032 (1998-12-01), Wann
patent: 5891440 (1999-04-01), Lansky
patent: 6030622 (2000-02-01), Shehadeh
patent: 6060063 (2000-05-01), Lansky
patent: 6361807 (2002-03-01), Aviram et al.
patent: 6375993 (2002-04-01), Aviram et al.
patent: 6387418 (2002-05-01), Aviram et al.
patent: 6440410 (2002-08-01), Yegorova
patent: 6641850 (2003-11-01), Aviram et al.
patent: 6794375 (2004-09-01), Sarama et al.
patent: 6977089 (2005-12-01), Aviram et al.
patent: 2002/0012710 (2002-01-01), Lansky
patent: 2003/0045473 (2003-03-01), Sarama et al.
patent: 2004/0156920 (2004-08-01), Kane
patent: 2005/0159483 (2005-07-01), Bassaganya-Riera
patent: 2005/0202103 (2005-09-01), Rajendran et al.
patent: 2 178 968 (1973-11-01), None
patent: 2178968 (1973-11-01), None
patent: 2380299 (1978-09-01), None
patent: 404124140 (1992-04-01), None
patent: 5320037 (1993-12-01), None
patent: 9110710 (1997-04-01), None
patent: 410298094 (1998-10-01), None
patent: 10298094 (1998-11-01), None
patent: 410298094 (1998-11-01), None
patent: 11243911 (1999-09-01), None
patent: 2088119 (1997-08-01), None
patent: 1251851 (1986-08-01), None
patent: 1442167 (1988-12-01), None
patent: WO 93/23069 (1993-11-01), None
patent: WO 95/22254 (1995-08-01), None
patent: WO 98/29129 (1998-07-01), None
patent: WO99/66941 (1999-12-01), None
patent: 0137848 (2001-05-01), None
Glozman et al. Khim.-Farm. Zh. 1989. vol. 23, No. 9, pp. 1111-1115—full English translation also enclosed.
International Product Alert Bulletin entitled “Rubyan Persia Pomegranate Concentrate Extract”. Dec. 15, 1997. Full text PROMT Abstract enclosed.
Pereira et al. Ciencia e Cultura (Sao Paulo). 1997. vol. 49, No. 5-6, pp. 354-358.
Aviram et al. Atherosclerosis. 2001. vol. 158, pp. 195-198.
Journal of Medicinal Food, 2004, (3) 305-308., Esmaillzadeh A. et al., Concentrated Pomegranate Juice Improves Lipid Profiles in Diabetic Patients with Hyperlipidemia.
British Journal of Pharmacology, 2005,145, 767-774, Huang TH. et al., Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: role of lowering circulating lipids.
Toxicology and Applied Pharmacology, 2005, 207:160-169, Huang TH et al., Anti-diabetic action ofPunica granatumflower extract: Activation of PPAR-γ and identification of an active component.
Journal of Ethnopharmacology, 2005, 99:239-244, Li Y. et al.,Punica granatumflower extract, a potent α-glucosidase inhibitor, improves postprandial hyperglycemia in Zucker Diabetic fatty rats.
Journal of Alternative and Complementary Medicine, 2004, 10(2):369-378, Saxena A., and Vikram NK, Role of Selected Indian Plants in Management of Type 2 Diabetes: A Review.
Ann. N.Y. Acad. Sci.,. 2004, 1030:434-441, Aggarwal BB. and Shishodia S., Suppression of the NF-κB Activation Pathways by Spice-Derived Phytochemicals.
D. Ziegler, Type 2 diabetes as an inflammatory cardiovacsular disorder, Curr Mol Med 5 (2005) pp. 309-322.
K. Wattanakit, A.R. Folsom and E. Selvin et al., Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study, Atheroscelerosis 180 (2005), pp. 389-397.
D. Aronson and E.J. Rayfield, How hyperglycemia promotes atheroscelerosis: molecular mechanisms, Cardiovasc Diabetol 1 (2002), p. 1.
A. Ceriello and E. Motz, Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited, Arterioscler Thromb Vasc Biol 24 (2004), pp. 816-823.
P. Martin-Gallan, A. Carrascosa, M. Gussinye and C. Dominguez, Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications, Free Radic Biol Med 34 (2003), pp. 1563-1574.
C.L. Whiteside, Cellular mechanisms and treatment of diabetes vascular complications converge on reactive oxygen species, Curr Hypertens Rep 7 (2005), pp. 148-154.
J.S. Johansen, A.K. Harris, D.J. Rychly and A. Ergul, Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice, Cardiovasc Diabetol 4 (2005), p. 5.
S. Park and S.B. Choi, Effects of alpha-tocopherol supplementation and continuous subcutaneous insulin infusion on oxidative stress in Korean patients with type 2 diabetes, Am J Clin Nutr 75 (2002), pp. 728-733.
A. Ceriello, N. Bortolotti and E. Motz et al., Red wine protects diabetic patients from metal-induced oxidative stress and thrombosis: a pleasant approach to the prevention of cardiovascular disease in diabetes, Eur J Clin Invest 31 (2001), pp. 322-328.
S.I. Rizvi, M.A. Zaid, R. Anis and N. Mishra, Protective role of tea catechins against oxidation-induced damage of type 2 diabetic erythrocytes, Clin Exp Pharmacol Physiol 32 (2005), pp. 70-75.
M.L. Gil, F.A. Tomas-Barberan, B. Hess-Pierce, D.M. Holcroft and A.A. Kader, Antioxidant activity of pomegranate juice and its relationship with phenolics composition and processing, J Agric Food Chem 10 (2000), pp. 4581-4589.
Aviram M. Pomegranate juice as a major source for polyphenolic flavonoids and it is most potent antioxidant against LDL oxidation and atherosclerosis. In: Pasquier C, editor. Proceedings of the XI Biennial Meeting of the Society for Free Radical Research International. Paris, France, Jul. 16-20, 2002. Monduzzi Editore S.P, AMEDIMOND Inc., pp. 523-528.
M. Aviram, L. Dornfeld and M. Rosenblat et al., Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice, Am J Clin Nutr 71 (2000), pp. 1062-1076.
M. Aviram, M. Rosenblat and D. Gaitini et al., Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation, Clin Nutr 23 (2004), pp. 423-433.
J.J. Boyle, Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture, Curr Vasc Pharmacol 3 (2005), pp. 63-68.
T. Naito, S. Oikawa, H. Kotake, K. Hayasaka and T. Toyota, Effect of glucose concentration on foam cell formation in THP-1 cells, J Atheroscler Thromb 8 (2001), pp. 55-62.
A.D. Dobrian, V. Lazar, C. Sinescu, D. Mincu and M. Simionescu, Diabetic state induces lipid loading and altered expression and secretion of lipoprotein lipase in human monocytes-derived macrophages, Atherosclerosis 153 (2000), pp. 191-201.
G. Ceolotto, A. Gallo and M. Miola et al., Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo, Diabetes 48 (1999), pp. 1316-1322.
Ling Li, S. Tatsuya and R. Genevieve, Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation, Circ Res 94 (2004), pp. 892-901.
K. Fukuhara-Takaki, M. Sakai, Y. Sakamoto, M. Takeya and S. Horiuchi, Expression of class a scavenger receptor is enhanced by high glucose in vitro under diabetic conditions in vivo: one mechanism for an increased rate of atherosclerosis in diabetes, J Biol Chem 280 (2005), pp. 3355-3364.
Hayek T, Hussein K, Aviram M, et al. Macrophage foam cell formation in streptozotocin-induced diabetic mice: stimulatory effect of glucose. Atherosclerosis, in press.
K.N. Gan, A. Smolen, H.W. Eckerson and Du B.N. La, Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities, Drug Metab Dispos 19 (1991), pp. 100-106
Delina Law Group, P.C.
Pom Wonderful, LLC
Tate Christopher R.
LandOfFree
Methods of using pomegranate extracts for treating diabetes... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using pomegranate extracts for treating diabetes..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using pomegranate extracts for treating diabetes... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4242016